Hepatitis C virus infection in ocular adnexal lymphomas

Arch Ophthalmol. 2010 Oct;128(10):1295-9. doi: 10.1001/archophthalmol.2010.233.

Abstract

Objective: To assess the influence of hepatitis C virus (HCV) infection on disease appearance and outcome of ocular adnexal non-Hodgkin lymphoma (ONHL).

Design: Retrospective comparative study (from January 1, 1992, through December 31, 2006).

Methods: The medical records of 129 patients with ONHL were retrospectively reviewed. All the patients were tested serologically for the presence of HCV infection. Patients were divided into 2 groups according to the presence or absence of HCV infection.

Main outcome measures: Prevalence of HCV infection, staging to evaluate the extent of disease at the onset, and clinical outcome data on overall and disease-free survival.

Results: The prevalence of HCV infection among the patients with ONHL was 17.8%. Seropositivity for HCV infection was significantly associated with extraorbital lymphoma at the onset (P = .006). High prevalence of mucosa-associated lymphoid tissue disease (79.8%) was registered. Protocol therapy included radiotherapy and chemotherapy, depending on the stage of the disease. Complete remission was achieved in 99 patients (76.7%). A total of 23.6% of patients with HCV-seronegative status and 21.7% of those with HCV-seropositive status experienced relapse of the lymphomatous disease. No significant differences in the 5-year overall survival and disease-free survival between the 2 groups were observed.

Conclusions: Prevalence of HCV infection in patients with ONHL is a relevant issue, accounting for 17.8% of the examined patients. Infection with HCV may influence the initial appearance of ONHL because it is associated with more widespread disease at the onset. However, the overall and disease-free survival of the infected patients are not statistically different than that of patients who are not infected.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Conjunctival Neoplasms / mortality
  • Conjunctival Neoplasms / pathology
  • Conjunctival Neoplasms / therapy
  • Conjunctival Neoplasms / virology
  • Disease-Free Survival
  • Eye Infections, Viral / mortality
  • Eye Infections, Viral / pathology
  • Eye Infections, Viral / therapy
  • Eye Infections, Viral / virology*
  • Eye Neoplasms / mortality
  • Eye Neoplasms / pathology
  • Eye Neoplasms / therapy
  • Eye Neoplasms / virology*
  • Eyelid Neoplasms / mortality
  • Eyelid Neoplasms / pathology
  • Eyelid Neoplasms / therapy
  • Eyelid Neoplasms / virology
  • Female
  • Hepatitis C / mortality
  • Hepatitis C / pathology
  • Hepatitis C / therapy
  • Hepatitis C / virology*
  • Humans
  • Lacrimal Apparatus Diseases / mortality
  • Lacrimal Apparatus Diseases / pathology
  • Lacrimal Apparatus Diseases / therapy
  • Lacrimal Apparatus Diseases / virology
  • Lymphoma, Non-Hodgkin / mortality
  • Lymphoma, Non-Hodgkin / pathology
  • Lymphoma, Non-Hodgkin / therapy
  • Lymphoma, Non-Hodgkin / virology*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Orbital Neoplasms / mortality
  • Orbital Neoplasms / pathology
  • Orbital Neoplasms / therapy
  • Orbital Neoplasms / virology
  • Prevalence
  • Radiotherapy
  • Retrospective Studies
  • Survival Rate

Substances

  • Antineoplastic Agents